OPK vs DBVT vs PRGO vs IQV vs CRL

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -14. 9% for OPKO Health, Inc. (OPK). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate OPKO Health, Inc. (OPK) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -70. 5% for OPKO Health, Inc. (OPK). Over 10 years, the gap is even starker: IQV returned +166. 6% versus OPK's -88. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), OPKO Health, Inc.

(OPK) is the lower-risk stock at 1. 19β versus Charles River Laboratories International, Inc. 's 1. 44β — meaning CRL is approximately 21% more volatile than OPK relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -14. 9% for OPKO Health, Inc. (OPK). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -37. 2% for OPKO Health, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -36. 1% for OPK. At the gross margin level — before operating expenses — PRGO leads at 35. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. OPK, DBVT, IQV, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

21), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, CRL: +114. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OPK is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock. PRGO pays a dividend while OPK, DBVT, IQV, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.